Reuters
GW said it had engaged U.S.-based Apjohn Group LLC, a 10-member group of former major U.S. pharmaceutical company executives with extensive experience in U.S. clinical development, regulatory affairs and public policy.
It also said U.S. founder investors had put a further $4.8 million into the business, taking their stake to 9.62 percent from 7.79 percent.
More...
|